Kronična limfocitna levkemija (KLL) je najpogostejša levkemija v zahodnem svetu. Pogosto je odkrita povsem naključno, večina bolnikov pa nikoli ne bo potrebovala zdravljenja. Pri teh, ki pa ga, se trenutno uporablja zdravljenje z zaviralci BKT in BCL2. Pri bolnikih moramo biti predvsem pozorni na pojav okužb in sekundarnih novotvorb, ob zdravljenju z zdravili pa na motnje srčnega ritma, krvni tlak in morebitni neugodni potek. Štirje specialisti hematologije pojasnjujejo posebnosti KLL in mesto zaviralcev BTK v zdravljenju te krvne bolezni.

Vsebino izobraževanja Kronična limfocitna levkemija - splošni poudarki za vsakega zdravnika si lahko ogledate v <a href="https://public.mediately.co/assets/wp-uploads/2023/11/22101856/CME-KLL-in-vloga-zaviralcev-BTK-pri-zdravljenju-Skerget-1.pdf">tej predstavitvi</a>.

Vsebino izobraževanja Zdravljenje kronične limfocitne levkemije si lahko ogledate v <a href="https://public.mediately.co/assets/wp-uploads/2023/11/22101852/CME-KLL-in-vloga-zaviralcev-BTK-pri-zdravljenju-Dreisinger.pdf">tej predstavitvi</a>.

Vsebino izobraževanja Uporaba zdravila akalabrutinib pri zdravljenju KLL si lahko ogledate v <a href="https://public.mediately.co/assets/wp-uploads/2023/11/22101850/CME-KLL-in-vloga-zaviralcev-BTK-pri-zdravljenju-Cemazar.pdf">tej predstavitvi</a>.

Vsebino izobraževanja Zaviralci BTK v zdravljenju KLL si lahko ogledate v <a href="https://public.mediately.co/assets/wp-uploads/2023/11/22101854/CME-KLL-in-vloga-zaviralcev-BTK-pri-zdravljenju-Grat.pdf">tej predstavitvi</a>.

<ol>
<li><a href="https://www.haematologica.org/atlas">Haematologica Atlas of Hematologic Cytology</a>. Haematologica. Retrieved July 14, 2023.</li>
<li>Podgornik, H., Pretnar, J., Černelč. P. “<a href="https://doi.org/10.3389/fimmu.2021.687458">Atlas krvnih celic</a>.” Ljubljana: Slovensko društvo za hematoonkološko diagnostiko, 2013.</li>
<li>Ahn, Inhye E., and Jennifer R. Brown. “Targeting Bruton’s Tyrosine Kinase in CLL.” Frontiers in Immunology, vol. 12, Frontiers Media, June 2021.</li>
<li><a href="https://www.ema.europa.eu/en/documents/product-information/calquence-epar-product-information_sl.pdf">POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA Calquence 100 mg trde kapsule</a>. European Medicine Agency. Retrieved July 14, 2023.</li>
<li>Sharman JP et al. Lancet. 2020; 395: 1278–91. 2. Sharman JP et al. Poster Presented at: ASCO Virtual Annual Meeting; June 4-8, 2021.</li>
<li>Sharman JP et al. Poster Presented at: ASCO; June 3-7, 2022; Chicago, Illinois.</li>
<li>Jurczak W et al. Poster presented at: ASCO; June 3-7, 2022; Chicago, Illinois. 2. Hallek M, et al. Blood. 2008;111(12):5446-56. </li>
<li><a href="https://www.uptodate.com/contents/treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia">Treatment of relapsed or refractory chronic lymphocytic leukemia</a>. UpToDate. Retrieved July 14, 2023.</li>
<li><a href="https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-124-acalabrutinib.pdf">Acalabrutinib monotherapy</a>. Oxford Health NHS Foundation Trust. Retrieved July 14, 2023.</li>
<li><a href="https://www.uptodate.com/contents/acalabrutinib-drug-information">Acalabrutinib Drug Information</a>. UpToDate. Retrieved July 14, 2023.</li>
<li>Linn, B S et al. “<a href="https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.1968.tb02103.x">Cumulative illness rating scale</a>.” Journal of the American Geriatrics Society vol. 16,5 (1968): 622-6.</li>
<li>Strati, Paolo et al. “<a href="https://onlinelibrary.wiley.com/doi/10.1111/bjh.14785">Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.</a>” British journal of haematologyvol. 178,3 (2017): 394-402.</li>
<li>Thurmes, Paul et al. “<a href="http://www.tandfonline.com/doi/full/10.1080/10428190701724785">Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia.</a>” Leukemia &amp; lymphoma vol. 49,1 (2008): 49-56.</li>
<li>Parikh, Sameer A et al. “<a href="https://www.nature.com/articles/s41375-020-0852-7">Chronic lymphocytic leukemia in 2020: a surfeit of riches?</a>.” Leukemia vol. 34,8 (2020): 1979-1983.</li>
<li>Eichhorst, B et al. “<a href="https://www.annalsofoncology.org/article/S0923-7534(20)42469-X/fulltext">Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</a>” Annals of oncology : official journal of the European Society for Medical Oncology vol. 32,1 (2021): 23-33.</li>
<li>Ghia et al. EHA 2021; EP636.</li>
<li>Barf, Tjeerd et al. “<a href="https://jpet.aspetjournals.org/content/363/2/240">Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.</a>” The Journal of pharmacology and experimental therapeutics vol. 363,2 (2017): 240-252.</li>
<li>Byrd, John C et al. “<a href="https://ascopubs.org/doi/10.1200/JCO.21.01210">Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.</a>” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,31 (2021): 3441-3452.</li>
<li>Bond, David A, and Jennifer A Woyach. “<a href="https://link.springer.com/article/10.1007/s11899-019-00512-0">Targeting BTK in CLL: Beyond Ibrutinib.</a>” Current hematologic malignancy reports vol. 14,3 (2019): 197-205.</li>
<li>Podoll, Terry et al. “<a href="https://jpet.aspetjournals.org/content/384/1/173">Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .</a>” The Journal of pharmacology and experimental therapeutics vol. 384,1 (2023): 173-186.</li>
<li>“<a href="https://www.eurofinsdiscovery.com/#panels-and-service">KINOMEscan® Technology Platform</a>.” Eurofins Discovery.</li>
<li>Seymour, John F., et al. “<a href="https://ashpublications.org/blood/article/140/Supplement%201/7050/487500/Assessing-the-Burden-of-Adverse-Events-in-a-Head">Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL).</a>” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 7050–52.</li>
<li>Roeker, Lindsey E., et al. “<a href="https://ashpublications.org/blood/article/140/Supplement%201/4156/491831/Comparing-Acalabrutinib-and-Ibrutinib-in-the-Real">Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients With Chronic Lymphocytic Leukemia.</a>” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 4156–58.</li>
<li>Kittai, Adam S et al. “<a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.27110">A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.</a>” American journal of hematology vol. 98,12 (2023): E387-E390.</li>
</ol>

Avtor/ji

Opravite izobraževanje in pridobite kreditne točke

Reference

Uporabite Mediately aplikacijo

Uporabite Mediately aplikacijo